Jingzhun Medical

Beijing Jingzhun Medical Technology Co., Ltd. is located in the Beijing Economic-Technological Development Area. Founded in June 2015, the company focuses on molecular diagnostics fields such as hematological oncology, organ and bone marrow transplantation, novel molecular pathology, and tumor immunotherapy testing. It is a high-tech enterprise integrating R&D, production, registration, manufacturing, sales, and service of molecular diagnostic reagents and instruments.
Adhering to the development philosophy of "Focusing on Molecular Diagnostics, Leading Precision Medicine," the company is guided by clinical market demand and uses its proprietary technology platforms as carriers, combining independent research and production with the introduction, absorption, and agency of external technologies to build a product portfolio and service chain for molecular diagnostics of related diseases. It has established comprehensive molecular diagnostic technology platforms including real-time fluorescence quantitative PCR, first-generation Sanger sequencing, second-generation high-throughput NGS sequencing, capillary electrophoresis fragment analysis, flow cytometry analysis, fluorescence in situ hybridization, and microfluidic chips. The company has undertaken National Science and Technology Major Projects and currently holds 46 authorized patents, including 16 invention patents, and 17 software copyrights. It has more than 40 products under development, has obtained 7 Class III registration certificates and more than 10 Class I registration certificates, and multiple products are in the clinical stage.
To date, the company's total investment exceeds RMB 400 million, and it has completed Series C financing. The company has been recognized with numerous honors and qualifications, including Beijing High-tech Enterprise, Zhongguancun High-tech Enterprise, Beijing-level Enterprise Science and Technology Research Institution, Member Unit of the Capital Science and Technology Conditions Platform, Beijing Intellectual Property Pilot Unit, Intellectual Property Application Pilot Unit of the Ministry of Industry and Information Technology, Zhongguancun Golden Seed Enterprise, "Yilin" Talent-founded Enterprise of the Beijing Economic-Technological Development Area, 2019 Beijing Yizhuang High-tech High-growth Top 20, Postdoctoral Research Workstation, Employee Innovation Studio, Beijing Specialized, Refined, Distinctive and Innovative (SRDI) Enterprise, 2020 Future Healthcare Top 100 Value Fields List Top 20 in Molecular Diagnostics, and Beijing Private Enterprise Top 100 SMEs. Meanwhile, the company has established deep cooperation with multiple well-known domestic and international enterprises and has carried out industry-university-research cooperation with several higher education institutions. It is committed to providing precise molecular diagnostic products and services for clinical medicine and strives to make significant contributions to improving the health of the Chinese people.
We will provide you with a broad platform and development space. We hope to work together with ambitious young people who share our dreams to create new dreams and new successes in the wave of precision medicine!
Our team adheres to the principles of ideals, philosophy, and rationality, and looks forward to your sincere joining!
We are confident that choosing is a kind of wisdom, and your choice is the beginning of success!